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COMMENT&RESPONSE
Cervical Pessary and Spontaneous PretermBirth
To the Editor Dr Saccone and colleagues1 conducted a ran-
domized clinical trial on the effect of a cervical pessary in
women with singleton pregnancies and short cervical
length and found that a pessary compared with no pessary
resulted in a lower rate of spontaneous preterm birth. The
authors achieved exactly their trial registry–planned sample
size of 300, with 100% follow-up and 100% adherence to
treatment allocation in both groups. The adherence seems
implausible, as my patients commonly request removal for
discomfort or other reasons.
In addition, exactly equal numbers of 150 women were
randomized to each group. Women were “randomized by a
web-based system … implemented by use of a central tele-
phone number.” According to the protocol, http://www
.randomization.com was used, and this can produce exactly
150 per group if 25 randomized blocks each of size 2, 4, and
6 are entered. But “randomization was stratified by cervical
length (≤20 mm or >20 mm to ≤25 mm),” so separate ran-
dom sequences must have been created for each stratum.
For example, in the stratum with cervical length more than
20 mm (Table 1 in the article), 17 women (150 minus 133)
were recruited in the pessary group and 25 (150 minus 125)
in the control group. This imbalance of 8 is impossible with
balanced blocks of 2, 4, and 6. At most, the imbalance
would be 3, if recruitment ended halfway through a block of
6 with 3 same allocations in a row.
There is also a problem with the Kaplan-Meier analysis
presented in the article’s Figure 2A (all delivery types) and
Figure 2B (spontaneous delivery only). The curves differ,
albeit not by much, but the numbers at risk at each gesta-
tion were identical. Could one of the sets of numbers at risk
be wrong?
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In Reply As Dr Thornton suggests, one of the strengths of our
trial was the 100% follow-up and the 100% adherence to the
treatment allocation in the pessary group. These high rates
were obtained because all women included in the trial deliv-
ered at the study institution. Moreover, included women
were extensively informed by the research staff about the
risk of preterm delivery. We strongly believe that all women
would keep a cervical pessary if clinicians clearly explained
to them that the benefits of having a healthy full-term infant
outweigh the risk of having discomfort. Indeed, almost all
women in the pessary group experienced some adverse
effects (86.7% had vaginal discharge and 3.3% had pelvic
discomfort) but none of them had the device removed.
Effective physician-patient communication is a central clini-
cal function in building a therapeutic relationship.1
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Regarding the randomization, women were randomized
byaweb-basedsystem(http://www.randomization.com)using
randomblocksof2,4,and6toreceivethepessaryornopessary.
Randomizationwas stratified by cervical length, and separate
randomization sequences were created by an independent
statistician. However, there was an error in the article. The
randomizationstratawere less than20mmandequalorgreater
than20mmtoequal or less than25mm,not equal or less than
20mmandgreater than 20mmto equal or less than 25mmas
stated. Using the erroneous cutoff would lead to imbalance
betweenthegroups, asThorntonsuggested.However,with the
correct cutoff,no imbalancewasnoticed,with 125womenwith
acervical length less than20mmand25womenwithacervical
lengthequalor greater than20mmtoequalor less than25mm
in each group. The number of women with a cervical length
equal or less than20mminTable 1was correct, as equal or less
than 20 mm was the cutoff used for vaginal progesterone
therapy, as recommendedbyguidelines.2 The article has been
corrected online andwe apologize for any confusion thismay
have caused.
Regarding the Kaplan-Meier curves, the numbers of
women at risk, reported in Figure 2, were the total number of
randomized women minus the number of women who al-
ready delivered, regardless of whether they had iatrogenic or
spontaneouspretermbirth.Therefore, thenumbersofwomen
at risk are the same for both curves.
The benefits of the pessary shown in our trial could be ex-
plainedby thehigh treatment adherence comparedwithother
trials. There are several ongoing trials evaluating the efficacy
of cervical pessary in prevention of preterm birth, and there
areplans for an individual patient datameta-analysis thatwill
includeourdata.Themeta-analysiswillupdateprior reviews3,4
and hopefullywill clarify the effect of cervical pessary in pre-
vention of preterm birth.
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Quality of Life in PatientsWith Glioblastoma Treated
With Tumor-Treating Fields
To the Editor In amultisite, randomized, phase 3, clinical trial,
Dr Stupp and colleagues1 demonstrated a modest benefit for
patients newly diagnosed with glioblastoma treated with tu-
mor-treating fields (TTFields) and temozolomide vs temozo-
lomide alone in progression-free survival (7.1 months for
TTFields plus temozolomide vs 4 months for temozolomide
alone) and overall survival (20.9months for TTFields plus te-
mozolomide vs 16 months for temozolomide alone). The au-
thors should justify the current cost of thedevice ($20000per
month) andalso thediscuss theeffectonqualityof life forboth
thepatients (shavingtheirhead)andfamilywhenpatientswear
the TTFields device 18 hours a day.
Cognitive (Mini-Mental State Examination) and func-
tional (Karnofsky performance score) metrics were included
in their analysis, but the use of standardized, health-related
quality-of-life scores (such as the European Organisation for
Research and Treatment of Cancer quality-of-life question-
naire and its brain-specific module) were not mentioned.
Tumor-treating fields plus temozolomide compared with te-
mozolomide alone showed no significant differences in time
to a sustained6-point decline in theMini-Mental StateExami-
nationscore.1 Standardizedhealth-relatedquality-of-life scores
take into account emotional, social, and role functioning.2
An interimanalysis conductedon the first 315 randomizedpa-
tients didnot showsignificant differences for anyof the func-
tional scalesoneitherquestionnaire ineither treatmentgroup.2
A larger analysis incorporating 92%of the patients noted that
42% of patients had not completed the questionnaires at the
1-year follow-up.3 Thephysical andemotional burdenof shav-
ing one’s head while wearing the device 18 hours a day
(includingwhile sleeping) cannot beunderestimated for both
patient and family members. In fact, it is the partner, friend,
or family member whomust change the adhesives, adminis-
ter scalp care, and adjust the TTFields device when it mal-
functions, even in the middle of the night.
Other trials, perhaps with less significant psychiatric
implications, may be better suited for patients with newly
diagnosed glioblastoma. For example, a phase 3 trial (CeTeg/
NOA-09) showed that the combination of lomustine and
temozolomide significantly improved median overall sur-
vival (37.9 months with lomustine, temozolomide, and radio-
therapy vs 31.4 months with temozolomide and radiotherapy
alone) in patients with the 06-methylguanine-DNA methyl-
transferase (MGMT) promoter.4
In sum,althoughTTFieldsplus temozolomideprovidesan
interestingand innovative treatment fornewlydiagnosedglio-
blastoma, a better understanding of the effect on patient and
family quality of life needs to be assessed, especially to jus-
tify TTField’s increased economic and emotional burden.
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